Optimizing	O
Survival	O
of	O
Patients	O
With	O
Marginally	O
Operable	O
Stage	B:C0278983
IIIA	I:C0278983
Non-Small	I:C0278983
-	I:C0278983
Cell	I:C0278983
Lung	I:C0278983
Cancer	I:C0278983
Receiving	O
Chemoradiotherapy	O

Optimizing	O
Survival	O
of	O
Patients	O
With	O
Marginally	O
Operable	O
Stage	O
IIIA	I:C0278983
Non-Small	I:C0278983
-	I:C0278983
Cell	I:C0278983
Lung	I:C0278983
Cancer	I:C0278983
Receiving	O
Chemoradiotherapy	B:C0436307

For	O
marginally	O
operable	O
stage	B:C0278983
IIIA	I:C0278983
non-small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
(	O
non-	O
small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
)	O
,	O
surgery	O
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	O
concurrent	O
chemoradiotherapy	I:C3178775
(	O
concurrent	O
chemoradiotherapy	I:C3178775
)	O
for	O
reasons	O
(	O
unresectable	O
or	O
medically	O
inoperable	O
conditions	O
,	O
or	O
patient	O
refusal	O
)	O
.	O

For	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
non-small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
(	O
non-	B:C0278983
small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
)	O
,	O
surgery	O
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	O
concurrent	O
chemoradiotherapy	I:C3178775
(	O
concurrent	O
chemoradiotherapy	I:C3178775
)	O
for	O
reasons	O
(	O
unresectable	O
or	O
medically	O
inoperable	O
conditions	O
,	O
or	O
patient	O
refusal	O
)	O
.	O

For	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
non-small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
(	O
non-	O
small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
)	O
,	O
surgery	O
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	B:C0600558
concurrent	O
chemoradiotherapy	I:C3178775
(	O
concurrent	O
chemoradiotherapy	I:C3178775
)	O
for	O
reasons	O
(	O
unresectable	O
or	O
medically	O
inoperable	O
conditions	O
,	O
or	O
patient	O
refusal	O
)	O
.	O

For	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
non-small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
(	O
non-	O
small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
)	O
,	O
surgery	O
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	O
concurrent	B:C3178775
chemoradiotherapy	I:C3178775
(	O
concurrent	O
chemoradiotherapy	I:C3178775
)	O
for	O
reasons	O
(	O
unresectable	O
or	O
medically	O
inoperable	O
conditions	O
,	O
or	O
patient	O
refusal	O
)	O
.	O

For	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
non-small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
(	O
non-	O
small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
)	O
,	O
surgery	O
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	O
concurrent	O
chemoradiotherapy	I:C3178775
(	O
concurrent	B:C3178775
chemoradiotherapy	I:C3178775
)	O
for	O
reasons	O
(	O
unresectable	O
or	O
medically	O
inoperable	O
conditions	O
,	O
or	O
patient	O
refusal	O
)	O
.	O

For	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
non-small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
(	O
non-	O
small	I:C0278983
-	I:C0278983
cell	I:C0278983
lung	I:C0278983
cancer	I:C0278983
)	O
,	O
surgery	O
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	O
concurrent	O
chemoradiotherapy	I:C3178775
(	O
concurrent	O
chemoradiotherapy	I:C3178775
)	O
for	O
reasons	O
(	O
unresectable	B:C1519810
or	O
medically	O
inoperable	O
conditions	O
,	O
or	O
patient	O
refusal	O
)	O
.	O

This	O
study	B:C2603343
aims	O
to	O
investigate	O
the	O
outcomes	O
of	O
a	O
phased	O
CCRT	I:C0040808
protocol	I:C0040808
established	O
to	O
maximize	O
the	O
operability	O
of	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
NSCLC	I:C0278983
and	O
to	O
care	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
in	O
comparison	O
with	O
continuous	O
-	I:C3178775
course	I:C3178775
definitive	I:C3178775
CCRT	I:C3178775
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
outcomes	O
of	O
a	O
phased	B:C0040808
CCRT	I:C0040808
protocol	I:C0040808
established	O
to	O
maximize	O
the	O
operability	O
of	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
NSCLC	I:C0278983
and	O
to	O
care	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
in	O
comparison	O
with	O
continuous	O
-	I:C3178775
course	I:C3178775
definitive	I:C3178775
CCRT	I:C3178775
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
outcomes	O
of	O
a	O
phased	O
CCRT	I:C0040808
protocol	I:C0040808
established	O
to	O
maximize	O
the	O
operability	O
of	O
marginally	O
operable	O
stage	B:C0278983
IIIA	I:C0278983
NSCLC	I:C0278983
and	O
to	O
care	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
in	O
comparison	O
with	O
continuous	O
-	I:C3178775
course	I:C3178775
definitive	I:C3178775
CCRT	I:C3178775
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
outcomes	O
of	O
a	O
phased	O
CCRT	I:C0040808
protocol	I:C0040808
established	O
to	O
maximize	O
the	O
operability	O
of	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
NSCLC	I:C0278983
and	O
to	O
care	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
in	O
comparison	O
with	O
continuous	B:C3178775
-	I:C3178775
course	I:C3178775
definitive	I:C3178775
CCRT	I:C3178775
.	O

Forty	O
-	O
seven	O
patients	O
with	O
marginally	O
operable	O
stage	B:C0278983
IIIA	I:C0278983
NSCLC	I:C0278983
receiving	O
concurrent	O
chemoradiotherapy	I:C3178775
were	O
included	O
.	O

Forty	O
-	O
seven	O
patients	O
with	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
NSCLC	I:C0278983
receiving	O
concurrent	B:C3178775
chemoradiotherapy	I:C3178775
were	O
included	O
.	O

Twenty	O
-	O
eight	O
patients	O
were	O
treated	O
with	O
our	O
phased	B:C0040808
CCRT	I:C0040808
protocol	I:C0040808
,	O
including	O
neoadjuvant	O
concurrent	O
chemoradiotherapy	I:C3178775
followed	O
by	O
surgery	O
(	O
group	O
A	O
,	O
n	O
=	O
16	O
)	O
or	O
,	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
maintenance	O
chemotherapy	I:C0481504
and	O
split	O
-	I:C3178775
course	I:C3178775
CCRT	I:C3178775
boost	O
(	O
group	O
B	O
,	O
n	O
=	O
12	O
)	O
.	O

Twenty	O
-	O
eight	O
patients	O
were	O
treated	O
with	O
our	O
phased	O
CCRT	I:C0040808
protocol	I:C0040808
,	O
including	O
neoadjuvant	B:C0600558
concurrent	O
chemoradiotherapy	I:C3178775
followed	O
by	O
surgery	O
(	O
group	O
A	O
,	O
n	O
=	O
16	O
)	O
or	O
,	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
maintenance	O
chemotherapy	I:C0481504
and	O
split	O
-	I:C3178775
course	I:C3178775
CCRT	I:C3178775
boost	O
(	O
group	O
B	O
,	O
n	O
=	O
12	O
)	O
.	O

Twenty	O
-	O
eight	O
patients	O
were	O
treated	O
with	O
our	O
phased	O
CCRT	I:C0040808
protocol	I:C0040808
,	O
including	O
neoadjuvant	O
concurrent	B:C3178775
chemoradiotherapy	I:C3178775
followed	O
by	O
surgery	O
(	O
group	O
A	O
,	O
n	O
=	O
16	O
)	O
or	O
,	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
maintenance	O
chemotherapy	I:C0481504
and	O
split	O
-	I:C3178775
course	I:C3178775
CCRT	I:C3178775
boost	O
(	O
group	O
B	O
,	O
n	O
=	O
12	O
)	O
.	O

Twenty	O
-	O
eight	O
patients	O
were	O
treated	O
with	O
our	O
phased	O
CCRT	I:C0040808
protocol	I:C0040808
,	O
including	O
neoadjuvant	O
concurrent	O
chemoradiotherapy	I:C3178775
followed	O
by	O
surgery	O
(	O
group	O
A	O
,	O
n	O
=	O
16	O
)	O
or	O
,	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
maintenance	B:C0481504
chemotherapy	I:C0481504
and	O
split	O
-	I:C3178775
course	I:C3178775
CCRT	I:C3178775
boost	O
(	O
group	O
B	O
,	O
n	O
=	O
12	O
)	O
.	O

Twenty	O
-	O
eight	O
patients	O
were	O
treated	O
with	O
our	O
phased	O
CCRT	I:C0040808
protocol	I:C0040808
,	O
including	O
neoadjuvant	O
concurrent	O
chemoradiotherapy	I:C3178775
followed	O
by	O
surgery	O
(	O
group	O
A	O
,	O
n	O
=	O
16	O
)	O
or	O
,	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
maintenance	O
chemotherapy	I:C0481504
and	O
split	B:C3178775
-	I:C3178775
course	I:C3178775
CCRT	I:C3178775
boost	O
(	O
group	O
B	O
,	O
n	O
=	O
12	O
)	O
.	O

The	O
other	O
19	O
were	O
treated	O
with	O
continuous	B:C3178775
-	I:C3178775
course	I:C3178775
definitive	I:C3178775
CCRT	I:C3178775
(	O
group	O
C	O
)	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
were	O
analyzed	B:C0936012
.	O

Among	O
all	O
,	O
median	O
OS	O
and	O
PFS	O
were	O
35.6	O
and	O
12.8	O
months	O
,	O
respectively	O
(	O
median	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
,	O
22.3	O
months	O
)	O
.	O

On	O
multivariate	O
analysis	O
,	O
performance	B:C1518965
status	I:C1518965
0	O
to	O
1	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.026	O
;	O
P	O
<	O
.001	O
)	O
,	O
adenocarcinoma	O
(	O
HR	O
,	O
0.156	O
;	O
P	O
=	O
.003	O
)	O
,	O
and	O
group	O
A	O
(	O
HR	O
,	O
0.199	O
;	O
P	O
=	O
.033	O
)	O
were	O
independent	O
prognostic	I:C1514474
factors	I:C1514474
.	O

On	O
multivariate	O
analysis	O
,	O
performance	O
status	I:C1518965
0	O
to	O
1	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.026	O
;	O
P	O
<	O
.001	O
)	O
,	O
adenocarcinoma	B:C0001418
(	O
HR	O
,	O
0.156	O
;	O
P	O
=	O
.003	O
)	O
,	O
and	O
group	O
A	O
(	O
HR	O
,	O
0.199	O
;	O
P	O
=	O
.033	O
)	O
were	O
independent	O
prognostic	I:C1514474
factors	I:C1514474
.	O

On	O
multivariate	O
analysis	O
,	O
performance	O
status	I:C1518965
0	O
to	O
1	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.026	O
;	O
P	O
<	O
.001	O
)	O
,	O
adenocarcinoma	O
(	O
HR	O
,	O
0.156	O
;	O
P	O
=	O
.003	O
)	O
,	O
and	O
group	O
A	O
(	O
HR	O
,	O
0.199	O
;	O
P	O
=	O
.033	O
)	O
were	O
independent	B:C1514474
prognostic	I:C1514474
factors	I:C1514474
.	O

For	O
marginally	O
operable	O
stage	B:C0278983
IIIA	I:C0278983
NSCLC	I:C0278983
,	O
our	O
phased	O
CCRT	I:C0040808
strategy	I:C0040808
may	O
optimize	O
survival	O
by	O
maximizing	O
operability	O
and	O
maintain	O
an	O
acceptable	O
survival	O
for	O
reassessed	O
inoperable	O
patients	O
by	O
split	O
-	I:C3178775
course	I:C3178775
CCRT	I:C3178775
boost	O
following	O
maintenance	O
chemotherapy	I:C0481504
.	O

For	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
NSCLC	I:C0278983
,	O
our	O
phased	B:C0040808
CCRT	I:C0040808
strategy	I:C0040808
may	O
optimize	O
survival	O
by	O
maximizing	O
operability	O
and	O
maintain	O
an	O
acceptable	O
survival	O
for	O
reassessed	O
inoperable	O
patients	O
by	O
split	O
-	I:C3178775
course	I:C3178775
CCRT	I:C3178775
boost	O
following	O
maintenance	O
chemotherapy	I:C0481504
.	O

For	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
NSCLC	I:C0278983
,	O
our	O
phased	O
CCRT	I:C0040808
strategy	I:C0040808
may	O
optimize	O
survival	O
by	O
maximizing	O
operability	O
and	O
maintain	O
an	O
acceptable	O
survival	O
for	O
reassessed	O
inoperable	O
patients	O
by	O
split	B:C3178775
-	I:C3178775
course	I:C3178775
CCRT	I:C3178775
boost	O
following	O
maintenance	O
chemotherapy	I:C0481504
.	O

For	O
marginally	O
operable	O
stage	O
IIIA	I:C0278983
NSCLC	I:C0278983
,	O
our	O
phased	O
CCRT	I:C0040808
strategy	I:C0040808
may	O
optimize	O
survival	O
by	O
maximizing	O
operability	O
and	O
maintain	O
an	O
acceptable	O
survival	O
for	O
reassessed	O
inoperable	O
patients	O
by	O
split	O
-	I:C3178775
course	I:C3178775
CCRT	I:C3178775
boost	O
following	O
maintenance	B:C0481504
chemotherapy	I:C0481504
.	O

